SANCO test is based on the VeriSeq technology from Illumina Inc. (USA) - the sequencing solution world leader. This technology allows to skip the intermediate DNA amplification stage, which reduces the risk of sample contamination and reduces the duration of the analysis. Fragments of extracellular maternal and fetal DNA are sequenced using the Whole Genome Sequencing (WGS) analysis, and the length of DNA molecules is carefully assessed. Next, data from the whole maternal genome and fetal cfDNA fraction are compared using bioinformatic analysis algorithms. Such actions allow assessing the risk of genetic abnormalities in a child resulting from excess or deficiency of chromosomes or their fragments. These methods also allow maintaining high test effectiveness even at low fetal DNA content - the result is obtained even at a content of 1% fetal cfDNA, and lack of result was recorded only for less than 1% of tests performed.

Thanks to this, there is a good chance that patients with a high BMI or those who have not obtained a result from other NIPT tests will receive SANCO test result without complications. Unlike other NIPT tests, medications and dietary supplements taken during pregnancy (e.g. Clexane) do not result in the inability to obtain a result or a second blood collection.

Compliance of the parameters of the new SANCO test has been confirmed by the European CE-IVD certificate for the entire technological process (high quality and reliability of the test has been validated and confirmed). Experience of the Genomed S.A. laboratory is confirmed by two EMQN (European Molecular Quality Network) certificates for non-invasive, prenatal genetic testing.